Akebia Therapeutics, INC Form 4 insider transactions

Erik Ostrowski, SVP, CFO, CBO & Treasurer of Akebia Therapeutics, Inc., reported a transaction involving the sale of 56,019 shares of common stock on June 29, 2026.

Philip J. Vickers, a Director at Akebia Therapeutics, Inc., reported the acquisition of stock options under the company's 2023 Plan.

Akebia Therapeutics CEO John P. Butler acquired 69,270 shares of common stock, simultaneously resolving a short-swing profit issue related to a prior sell-to-cover transaction.

Akebia Therapeutics' SVP and Chief Accounting Officer, Richard C. Malabre, sold shares to cover tax withholding obligations related to RSU vesting.

Akebia Therapeutics' Chief Commercial Officer, Nicholas Grund, sold 84,829 shares of common stock to cover tax withholding obligations related to RSU vesting.

Akebia Therapeutics' Chief Medical Officer, Steven Burke, sold 67,658 shares of common stock for tax withholding purposes related to RSU vesting.

Akebia Therapeutics' SVP, Chief Legal Officer, Carolyn M. Rucci, sold 69,772 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Akebia Therapeutics' SVP, CFO, CBO & Treasurer, Erik Ostrowski, sold 34,951 shares of common stock at $1.39 per share to cover tax withholding obligations related to vested restricted stock units.

Akebia Therapeutics CEO John P. Butler reported the vesting of restricted and performance stock units and subsequent tax-related sales of common stock.

Akebia Therapeutics' Chief Commercial Officer, Nicholas Grund, was granted 204,000 restricted stock units and 320,000 stock options on January 30, 2026.

Akebia Therapeutics' SVP and Chief Medical Officer, Steven Keith Burke, was granted 204,000 restricted stock units and 320,000 stock options.

Akebia Therapeutics, Inc. granted its SVP, Chief Legal Officer, Carolyn M. Rucci, 190,000 restricted stock units and 270,000 stock options.

Akebia Therapeutics' SVP and Chief Accounting Officer, Richard C. Malabre, received 79,000 restricted stock units and 119,000 stock options, aligning executive incentives with long-term company performance.

Akebia Therapeutics' SVP, CFO, CBO & Treasurer, Erik Ostrowski, was granted 204,000 restricted stock units and options to purchase 320,000 shares of common stock.

Akebia Therapeutics CEO and President John P. Butler was granted 743,000 restricted stock units and 1,115,000 stock options, effective January 30, 2026.

Akebia Therapeutics' SVP, CFO, CBO & Treasurer, Erik Ostrowski, sold 41,314 shares of common stock at $3.67 per share on June 30, 2025, to cover tax withholding obligations related to restricted stock unit vesting under a Rule 10b5-1 plan.

Akebia Therapeutics, Inc. director LeAnne M. Zumwalt was granted 35,700 restricted stock units and options to purchase 53,600 shares of common stock as part of her compensation.

Akebia Therapeutics, Inc. Director Adrian Adams reported the acquisition of 35,700 restricted stock units and options to purchase 53,600 shares of common stock as part of his compensation package.

Akebia Therapeutics, Inc. Director Myles Wolf was granted 35,700 restricted stock units and options to purchase 53,600 shares of common stock as part of the company's non-employee director compensation program.

Akebia Therapeutics, Inc. Director Cynthia Smith was granted 35,700 restricted stock units and options to purchase 53,600 shares of common stock as part of her compensation.

Akebia Therapeutics, Inc. Director Michael W. Rogers was granted 35,700 restricted stock units and options to purchase 53,600 shares of common stock as part of the company's non-employee director compensation program.

Akebia Therapeutics, Inc. Director Steven C. Gilman was granted 35,700 restricted stock units and options to purchase 53,600 shares of common stock on June 10, 2025, as part of the company's non-employee director compensation program.

Akebia Therapeutics Director Ronald Frieson was granted 35,700 restricted stock units and 53,600 stock options as part of his compensation, aligning his interests with the company's long-term performance.

Richard C. Malabre, SVP and Chief Accounting Officer of Akebia Therapeutics, Inc., completed a pre-arranged exercise of stock options and subsequent sale of common stock totaling 15,000 shares on June 9, 2025, under a Rule 10b5-1 plan.

Akebia Therapeutics' SVP and Chief Accounting Officer, Richard C. Malabre, sold 13,334 shares of common stock on June 4, 2025, as part of a pre-scheduled Rule 10b5-1 trading plan.

Akebia Therapeutics CEO John P. Butler sold 46,409 shares of common stock on March 3, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Steven Keith Burke, SVP, Chief Medical Officer of Akebia Therapeutics, sold 7,144 shares of common stock at $1.83 per share to cover tax withholding obligations.

Akebia Therapeutics CEO John P. Butler reports acquisition and disposal of company stock and derivative securities, including grants of restricted stock units and stock options.

Steven Burke, SVP, Chief Medical Officer of Akebia Therapeutics, reports acquisition and disposal of company stock and stock options.

Richard C. Malabre, SVP and Chief Accounting Officer of Akebia Therapeutics, reports acquisition and disposal of company stock and stock options.